Tag: psychotropics

🧠 Esketamine + Antidepressants in TRD: Does the Combo Matter?

📢 New data from a real-world study of 50,000+ patients with treatment-resistant depression (TRD) published in JAMA Psychiatry:

📌 Study Question:
Does combining esketamine with an SSRI or SNRI affect long-term outcomes in TRD?

📊 Key Findings (5-Year Follow-Up):

  • ✅ Esketamine + SNRI:
     ↘️ Lower all-cause mortality
     ↘️ Fewer hospitalizations
     ↘️ Reduced depressive relapse
  • ✅ Esketamine + SSRI:
     ↘️ Lower incidence of suicide attempts
  • 🔒 Overall: Low rates of adverse outcomes in all groups

💡 Clinical Implications:

  • Not all combinations are equal—pairing matters.
  • Esketamine + SNRI may be preferred for reducing relapse/mortality
  • Esketamine + SSRI may be considered in patients at risk for suicide
  • Personalized treatment decisions can enhance outcomes in TRD

🔍 More than symptom relief—it’s about survival, stability, and safety.

0

🚨 New Study Links Antidepressant Use to Significant Weight Gain Over 6 Years! 

A recent study published in Frontiers in Psychiatry reveals that individuals using antidepressants experienced notable weight gain over a six-year period.​

Key Findings:

  • Increased Weight Gain:​
    • Participants who used antidepressants showed an average weight increase of approximately 2% of their baseline body weight compared to non-users.​
  • Higher Obesity Risk:​
    • Those without obesity at the study’s start had double the risk of becoming obese if they used antidepressants throughout the six years.​

Implications:

With the widespread use of antidepressants and the global obesity epidemic, integrating weight management and metabolic monitoring into depression treatment plans is crucial.​

link: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1464898/full

0

Major Federal Healthcare Cuts: What Physicians Need to Know and How We Can Respond

A devastating blow to public health: More than $12 billion in federal grants—funding that supported infectious disease tracking, mental health services, addiction treatment, and other critical programs—has been canceled as part of recent federal budget cuts.

These cuts threaten early detection of outbreaks, access to psychiatric care, and lifesaving addiction treatment programs—all areas where we, as physicians, see the impact daily.

Key Areas Affected:

🚨 Infectious Disease Surveillance – Reduced ability to track emerging threats like COVID-19, flu, and antibiotic-resistant infections.
🧠 Mental Health Services – Fewer resources for crisis response teams, community mental health centers, and psychiatric services.
💉 Addiction Treatment – Less funding for MAT (medication-assisted treatment) and harm reduction programs at a time when overdose rates remain high.
🏥 Public Health Preparedness – Cuts to pandemic readiness and emergency response training for healthcare workers.

What Can We Do?

🔹 Advocate – Contact legislators, professional organizations (APA, AMA, ACP), and demand restoration of funding.
🔹 Educate – Inform patients and communities about how these cuts impact their care.
🔹 Mobilize – Work with hospital leadership and local organizations to find alternative funding sources.
🔹 Collaborate – Strengthen interprofessional partnerships to sustain services despite budget constraints.

We’ve seen what happens when public health is underfunded—it costs more lives and more money in the long run. We can’t afford to be silent.

0

Olanzapine vs. Quetiapine for Stimulant Psychosis: Is One the Clear Winner?

There is limited high-quality randomized controlled trial (RCT) evidence specifically comparing Zyprexa (olanzapine) or Seroquel (quetiapine) for the treatment of stimulant-induced psychosis (SIP), including cocaine-induced psychosis. However, some RCTs and observational studies provide useful insights:

Olanzapine (Zyprexa)

  • RCT Evidence:
    • A 2022 meta-analysis of antipsychotic treatments for stimulant-induced psychosis included olanzapine and found it to be effective in reducing positive psychotic symptoms, often comparable to haloperidol but with a better side effect profile (less extrapyramidal symptoms) 11.
    • A double-blind RCT comparing olanzapine vs. haloperidol in methamphetamine-induced psychosisfound that both were effective at reducing PANSS (Positive and Negative Syndrome Scale) scores, but olanzapine was associated with better tolerability 22.
    • Another RCT in methamphetamine-induced psychosis compared olanzapine and risperidone, showing similar efficacy but better tolerability with olanzapine 33.

Quetiapine (Seroquel)

  • RCT Evidence:
    • A small RCT in methamphetamine-induced psychosis found that quetiapine was effective but tended to require higher doses to achieve symptom resolution 44.
    • A retrospective study on cocaine-induced psychosis suggested that quetiapine may help reduce symptoms, but data is weaker compared to olanzapine or risperidone 55.
    • Quetiapine has also been studied as an option for reducing cocaine cravings, but results are mixed and it is generally less preferred for acute agitation compared to faster-acting options like olanzapine.

Head-to-Head Comparison

There is no direct RCT comparing olanzapine vs. quetiapine for stimulant-induced psychosis, but based on available data:

  • Olanzapine is generally preferred for acute agitation and psychosis because of its faster onset and greater D2 blockade.
  • Quetiapine may be useful in milder cases or for individuals needing sedation, but higher doses are often required.

Clinical Implications

  • For acute stimulant-induced psychosis, olanzapine (5–10 mg IM or PO) is a common first-line option due to rapid onset and favorable side effect profile.
  • Quetiapine (200–400 mg PO) can be considered, particularly for patients needing sedation or those with comorbid conditions like bipolar disorder.
  • Other antipsychotics with strong evidence include risperidone and haloperidol (though the latter has more extrapyramidal risk).

After reviewing the available literature, direct randomized controlled trials (RCTs) comparing olanzapine (Zyprexa) and quetiapine (Seroquel) for stimulant-induced psychosis (SIP), including cocaine-induced psychosis, remain scarce. However, some studies provide relevant insights:

Olanzapine (Zyprexa):

  • Efficacy: A randomized, double-blind trial compared olanzapine and haloperidol in patients with amphetamine-induced psychosis. Both medications effectively improved psychotic symptoms in the short term, with olanzapine showing a faster onset of action.

Quetiapine (Seroquel):

  • Efficacy: A double-blind RCT compared haloperidol and quetiapine for methamphetamine-induced psychosis. While both medications reduced psychotic symptoms, quetiapine appeared to have a more favorable profile in reducing certain symptoms over time. 

Indirect Comparisons:

  • First-Episode Psychosis: A 52-week randomized, double-blind study evaluated olanzapine, quetiapine, and risperidone in early psychosis patients. All three antipsychotics demonstrated comparable effectiveness, as indicated by similar rates of treatment discontinuation.

Conclusion:

While direct RCT evidence comparing olanzapine and quetiapine specifically for stimulant-induced psychosis is limited, existing studies suggest that both medications are effective in managing such conditions. Olanzapine may offer a faster onset of symptom relief, whereas quetiapine might present a more favorable side effect profile. Clinical decisions should be individualized, considering factors such as patient history, specific symptomatology, and potential side effects.

0

Can Creatine Boost Therapy for Depression? New Study Says Maybe!

A recent 8-week double-blind, randomized, placebo-controlled trial investigated whether oral creatine monohydrate (5g/day) could enhance the effects of cognitive-behavioral therapy (CBT) in treating major depressive disorder (MDD)—especially in under-resourced areas where access to treatment is limited.

🔬 Why Does This Matter?
While CBT is a gold-standard therapy for depression, many patients do not achieve full remission. This study explored whether creatine—widely used for muscle and brain energy metabolism—could provide an extra boost to treatment.

🧠 Key Findings:
✅ Participants receiving creatine + CBT had greater reductions in depression symptoms (measured by the Hamilton Depression Rating Scale) compared to those receiving placebo + CBT
✅ Reported improvements in mood, energy levels, and cognitive function
✅ Creatine was well-tolerated, with no significant safety concerns
✅ CBT was delivered once weekly by trained therapists

⚠️ Study Limitations:
🔹 Small sample size—larger studies are needed to confirm these findings
🔹 Short trial duration—long-term effects are still unknown
🔹 Study population—results may not generalize to all individuals with MDD

💡 What’s Next?
If larger studies confirm these results, creatine could become an accessible, affordable adjunct to therapy, particularly in communities with limited mental health resources.

What do you think? Could a common fitness supplement help improve mental health? Let’s discuss! ⬇️

link to study: https://www.sciencedirect.com/science/article/pii/S0924977X24007405

0

Managing Mild to Severe Depression: A Guide to Treatment Approaches

It is crucial to recognize that none of the available medications or neuromodulation procedures, including electroconvulsive therapy (ECT) and psychedelics, are disease-modifying. This means that while these treatments can alleviate symptoms, they do not address the underlying causes of depression. Think of them like acetaminophen for a fever—it may temporarily reduce the fever, but without treating the underlying infection, the fever will return.

Neuromodulation refers to techniques that alter brain activity through electrical or magnetic stimulation. Examples include ECT, transcranial magnetic stimulation (TMS), and vagus nerve stimulation (VNS), all of which have been explored as treatments for severe depression.

Optimizing Depression Treatment for Different Severity Levels

Given this understanding, how can we best utilize these treatments to support patients during difficult times? The key is to acknowledge that medications and neuromodulation primarily serve as symptom management tools, most effectively used in the short term for severe cases.

Mild to Moderate Depression: Prioritizing Non-Medication Approaches

For individuals experiencing mild to moderate depression, medication should not be the first line of treFor individuals experiencing mild to moderate depression, medication should not be the first line of treatment. Many people can directly link their depressive symptoms to stressful life events. In such cases, the best initial approach includes:

  • Cognitive Behavioral Therapy (CBT) – Evidence-based therapy that helps reframe negative thinking patterns. Research has shown that CBT is as effective as antidepressants for mild to moderate depression, with relapse rates significantly reduced in those who complete therapy.
  • Lifestyle Modifications – Regular exercise and a healthy diet have strong evidence supporting their role in reducing depressive symptoms. A study published in JAMA Psychiatry found that individuals engaging in at least 150 minutes of moderate exercise per week had a 25% lower risk of developing depression.

For some, these interventions alone may be sufficient to overcome depression and maintain long-term well-being. If additional support is needed, natural supplements with reasonable evidence, such as St. John’s Wort and S-Adenosylmethionine (SAMe), may be considered for mild to moderate depression. However, these supplements are not without risks—St. John’s Wort can interact with many medications, including antidepressants and birth control pills, potentially reducing their effectiveness. SAMe may cause gastrointestinal discomfort or manic symptoms in individuals with bipolar disorder.

Severe Depression: When Medication and Neuromodulation Play a Role

For individuals with severe depression, particularly those at risk for self-harm or suicide, the risks and benefits of medication should be carefully weighed. Antidepressants and neuromodulation therapies have demonstrated the most significant impact in these cases. When selecting a medication, I prioritize those with a lower risk of concerning side effects, particularly sexual dysfunction. My initial choices often include:

  • Bupropion – A dopamine-norepinephrine reuptake inhibitor with a favorable side effect profile.
  • Vortioxetine – Known for its cognitive benefits and relatively low sexual side effects.
  • Mirtazapine – Can be beneficial for those with sleep disturbances or appetite loss.
  • Vilazodone – A serotonin modulator with a lower incidence of sexual dysfunction compared to SSRIs.

It is essential for patients starting antidepressants to be closely monitored, especially in the early weeks of treatment, to assess for side effects and response. Regular follow-ups with a healthcare provider can help adjust dosages or explore alternative treatments if needed.

Treatment Duration and Discontinuation Considerations

For those starting medication, I generally recommend continuing treatment for 6 to 12 months, followed by an assessment to determine whether tapering off is feasible. This process involves shared decision-making, considering:

  • Symptom severity and stability
  • Level of daily functioning
  • Patient’s goals and preferences

The goal is to ensure that the patient has developed effective coping strategies, engaged in therapy, and adopted a healthy lifestyle before considering medication discontinuation. If stopping medication is not advisable, we work to identify the lowest effective dose for long-term maintenance.

Final Thoughts

Depression treatment should be personalized and dynamic, evolving with the patient’s needs. By recognizing that medications and neuromodulation are tools for symptom management rather than cures, we can ensure they are used effectively—providing relief during crises while prioritizing long-term strategies for resilience and recovery.

0

Can Low-Dose LSD Treat ADHD? A New Study Weighs In

ADHD (Attention-Deficit/Hyperactivity Disorder) affects millions of adults worldwide, with stimulants like methylphenidate and amphetamine being the most effective treatments. But could psychedelics like LSD offer an alternative? A new randomized clinical trial aimed to find out.

👉 Study Overview:

  • Design: Multicenter, double-blind, placebo-controlled trial (N = 53)
  • Participants: Mean age 37 years, 42% female
  • Intervention: Low-dose LSD (20 μg) or placebo twice weekly for 6 weeks (12 doses total)
  • Primary Outcome: Change in ADHD symptoms using the Adult ADHD Investigator Symptom Rating Scale (AISRS)

💡 Key Findings:

  • Both groups showed significant improvement in ADHD symptoms:
    • LSD group: −7.1 points (95% CI, −10.1 to −4.0)
    • Placebo group: −8.9 points (95% CI, −12.0 to −5.8)
  • ✅ LSD was safe and well tolerated
  • ❌ No significant difference between LSD and placebo in symptom reduction

🧠 What This Means:
While low-dose LSD was safe, it didn’t outperform placebo in treating ADHD symptoms. This challenges anecdotal claims about psychedelics for ADHD and reinforces the need for rigorous placebo-controlled trials in psychedelic research.

📈 Future research may explore higher doses or alternative mechanisms—but for now, stimulants remain the gold standard for ADHD treatment.

🔗 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2831639

0

Female Physicians at Higher Risk for Suicide: Key Findings

A February 26, 2025 study in JAMA Psychiatry reveals alarming trends in physician suicide rates:

📊 Key Findings

🔹 Female physicians face a significantly higher suicide risk compared to the general U.S. population.
🔹 Male physicians have a lower suicide risk than their nonphysician counterparts.

💡 Why This Matters

These statistics underscore a deeper systemic issue within healthcare
➡️ “Physicians face immense pressure, long hours, and high-stakes decisions, which contribute to burnout and mental health struggles.”

Failure to address these issues can lead to increased physician turnover, lower quality of care, and worsening healthcare outcomes for patients.

✅ What Can Be Done

✔️ Reduce stigma around mental health in medical culture.
✔️ Implement confidential mental health resources specifically for physicians.
✔️ Encourage work-life balance through adjusted schedules and peer support programs.
✔️ Offer routine mental health check-ins as part of employee wellness programs.

📞 Where to Get Help

🆘 If you or someone you know is struggling, help is available:
➡️ Call or text 988 for free, confidential support 24/7.
➡️ Visit the Physician Support Line at www.physiciansupportline.com — available 7 days a week with support from licensed psychiatrists.

💙 It’s time to support those who care for us.

0

Challenges of Antidepressant Management in Primary Care

Discussions about the potential overprescribing of antidepressants must begin with an understanding of who is doing most of the prescribing. In the U.S., primary care physicians (PCPs) write the majority of antidepressant prescriptions, with estimates suggesting that 60–80% originate from primary care rather than psychiatry (Mojtabai & Olfson, 2011; Mark et al., 2014). This prescribing pattern reflects broader trends in mental health treatment, where primary care has become the frontline for managing depression and other mood disorders.

Several factors contribute to this dynamic:

  • Limited access to psychiatrists: Many patients, especially in rural or underserved areas, face long wait times or geographic barriers to seeing a psychiatrist.
  • Overlap with medical conditions: PCPs frequently manage conditions like chronic pain, insomnia, and fatigue, for which antidepressants may be considered as part of the treatment plan.
  • Continuity of care: Patients often have longstanding relationships with their primary care providers, making them more comfortable discussing mood symptoms in this setting.
  • Psychiatric referral limitations: Many psychiatrists focus on complex or treatment-resistant cases, meaning initial treatment often falls under primary care.

Challenges and Considerations

While primary care plays a crucial role in mental health treatment, concerns exist regarding the effectiveness of antidepressant management in this setting:

  • Suboptimal dosing and medication selection: Studies suggest that antidepressants prescribed in primary care settings may be dosed too low or not adequately adjusted, potentially leading to partial response or treatment failure (Carrasco & Sandner, 2005). Additionally, there is a higher likelihood of using older antidepressants, which may have a less favorable side effect profile.
  • Lack of therapy integration: Guidelines recommend a combination of medication and psychotherapy for moderate-to-severe depression (APA, 2010), yet PCPs may have limited time, training, or referral resources to ensure therapy is included.
  • Potential misdiagnosis: Depressive symptoms can overlap with other psychiatric and medical conditions, leading to misdiagnosis or inappropriate treatment. For example, bipolar disorder is often misdiagnosed as major depressive disorder in primary care, which can result in inadequate treatment and risk of mood destabilization (Hirschfeld et al., 2003).

Addressing These Challenges

Several strategies can improve antidepressant management within primary care settings:

  • Collaborative care models: Studies show that integrating mental health professionals within primary care teams leads to improved outcomes, including higher remission rates and better adherence (Archer et al., 2012).
  • Standardized screening and follow-up: Implementing tools like the PHQ-9 for monitoring depression severity can help guide treatment decisions and ensure timely adjustments.
  • Education and decision support: Providing PCPs with continuing education on psychiatric prescribing and decision-support tools can enhance treatment precision.
  • Improved access to therapy: Expanding tele-therapy options and embedding behavioral health providers in primary care clinics can help bridge the gap between medication and psychotherapy.

Conclusion

Given the high volume of antidepressant prescriptions originating from primary care, ensuring optimal management is critical to improving patient outcomes. Strengthening collaboration between PCPs and mental health specialists, enhancing diagnostic accuracy, and integrating therapy referrals can help address current limitations.

Call to Action: If you are a healthcare professional involved in prescribing antidepressants, what strategies have you found effective in improving patient outcomes? Share your insights and experiences below.

0

What Happens When We Ignore Scientific Evidence?

When we reject the overwhelming scientific consensus that vaccines do not cause autism, we enter a dangerous world—one where facts are disregarded, misinformation thrives, and preventable diseases make a deadly comeback.

The Real Consequences of Vaccine Hesitancy

Vaccine hesitancy isn’t just a debate—it has real, measurable consequences

Measles Outbreaks: In early 2025, Texas experienced its most severe measles outbreak in nearly 30 years, with 198 confirmed cases as of March 7. The outbreak has resulted in 23 hospitalizations and one measles-related death—the first in the nation in a decade. The outbreak is primarily concentrated in rural Gaines County, where vaccination rates are notably low.

Whooping Cough Resurgence: Cases of pertussis (whooping cough) have increased in areas with lower vaccination rates, endangering infants who are too young to be fully vaccinated.

Polio’s Return: In 2022, a case of paralytic polio emerged in New York, decades after the disease had been eliminated in the U.S., traced back to vaccine hesitancy and low immunization coverage.

Ignoring evidence doesn’t just impact individuals—it threatens public health as a whole

Addressing Concerns: Why the Autism Myth Persists

Some parents worry about vaccine safety due to outdated or misleading claims, most notably a fraudulent 1998 study linking vaccines to autism. This study was retracted, and extensive research—including studies on hundreds of thousands of children—has confirmed no link between vaccines and autism. Yet, fear and misinformation persist, fueled by social media echo chambers and distrust in institutions.

While vaccine side effects do exist, they are typically mild (e.g., temporary soreness, fever) and far outweighed by the risks of the diseases they prevent. Scientific inquiry should always continue, but dismissing decades of rigorous research in favor of debunked myths endangers lives.

What Can We Do?

Combatting vaccine misinformation requires action. Here’s how you can help

✔ Speak Up: Correct misinformation when you see it, whether online or in conversations with friends and family.

✔ Rely on Experts: Trust reputable sources like the CDC, WHO, and medical professionals rather than social media influencers or unverified websites.

✔ Advocate for Science Education: Supporting critical thinking and scientific literacy helps build a society that values evidence over fear.

✔ Get Vaccinated: Lead by example—being up to date on vaccines protects you and those around you, especially vulnerable populations.

Science Is Not an Opinion

Truth is not subjective. If we abandon scientific evidence in favor of belief alone, we risk more than just vaccine-preventable diseases—we risk an era where facts no longer matter. The stakes are too high to let misinformation win.

0

Powered by WordPress.com.

Up ↑